Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. Nogami N, et al. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7. J Thorac Oncol. 2022. PMID: 34626838 Free article. Clinical Trial.
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Takiguchi Y, Seto T, Ichinose Y, Nogami N, Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, Nishikawa M, Watanabe K. Takiguchi Y, et al. Among authors: nogami n. J Thorac Oncol. 2011 Jan;6(1):156-60. doi: 10.1097/JTO.0b013e3181f7c76a. J Thorac Oncol. 2011. PMID: 21107293 Free article. Clinical Trial.
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M. Nogami N, et al. Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18. Lung Cancer. 2011. PMID: 21334093 Free article. Clinical Trial.
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T. Okamoto I, et al. Among authors: nogami n. Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Invest New Drugs. 2013. PMID: 23475281 Clinical Trial.
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. Seto T, et al. Among authors: nogami n. Lancet Oncol. 2013 Jun;14(7):590-8. doi: 10.1016/S1470-2045(13)70142-6. Epub 2013 Apr 30. Lancet Oncol. 2013. PMID: 23639470 Clinical Trial.
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Ichihara E, et al. Among authors: nogami n. J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434. J Thorac Oncol. 2015. PMID: 25695221 Free article. Clinical Trial.
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y. Hotta K, et al. Among authors: nogami n. Clin Lung Cancer. 2016 Jan;17(1):75-9. doi: 10.1016/j.cllc.2015.08.004. Epub 2015 Aug 18. Clin Lung Cancer. 2016. PMID: 26387039 Clinical Trial.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Takeda M, et al. Among authors: nogami n. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828788 Free article. Clinical Trial.
Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K. Kozuki T, et al. Among authors: nogami n. BMC Cancer. 2016 May 12;16:306. doi: 10.1186/s12885-016-2338-6. BMC Cancer. 2016. PMID: 27177035 Free PMC article.
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K. Yoh K, et al. Among authors: nogami n. Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4. Lancet Respir Med. 2017. PMID: 27825616 Clinical Trial.
128 results